Clinical trial
Effect of Androgel on Type 2 Diabetic Males With Hypogonadism
NCT00350701 · University at Buffalo, Other · Completed
Key facts
| NCT number | NCT00350701 |
|---|---|
| Title | Effect of Androgel on Type 2 Diabetic Males With Hypogonadism |
| Official title | Effect of Androgel on Inflammatory Mediators and Oxidative Stress in Type 2 Diabetic Males With Hypogonadism |
| Lead sponsor | University at Buffalo, Other |
| Collaborators | Solvay Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus Type 2 |
| Intervention type | Drug |
| Interventions | androgel, androgel 10g, placebo |
| Enrollment | 49 |
| Start date | Jul 1, 2006 |
| Primary completion | Jun 1, 2013 |
| Completion | Jul 1, 2013 |
| First posted | Jul 11, 2006 |
| Last update posted | Feb 10, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: